~~We~~ Claim~~s~~

~~1. A method of decreasing serum ALT levels, in a patient in need thereof comprising administering an effective amount of methazolamide to said patient.~~

~~2. A method of treating or preventing liver dysfunction in a patient in need thereof, comprising administering an effective amount of methazolamide to said patient.~~

~~3. A method for reducing liver lipid content in patient in need thereof, comprising administering an effective amount of methazolamide to said patient.~~

~~4. A method for treating or preventing NAFLD in a patient in need thereof comprising administering an effective amount of methazolamide to said patient.~~

~~5. The method according to claim 4 for treating or preventing NAFL.~~

~~6. The method according to claim 4 for treating or preventing NASH.~~

~~7. The method according to any one of claims 1 to 6 wherein the patient suffers from elevated ALT levels.~~

~~8. The method according to any one of claims 1 to 6 wherein the patient is also pre-diabetic or diabetic.~~

~~9. The method according to claim 8 wherein the patient has an HbA_{1c} level of ≥6.5%.~~

~~10. The method according to any one of claims 1-9 wherein the methazolamide is administered in combination with an anti-diabetic agent,~~

~~11. The method according to claim 10 wherein the anti-diabetic agent is metformin or a~~

~~phrmaceutically acceptable salt thereof.~~

1~~12~~. Use of methazolamide in the manufacture of a medicament for decreasing elevated serum alanine transaminase (ALT) ~~ALT~~ levels in a patient, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.

2~~13~~. Use of methazolamide in the manufacture of a medicament for treating or preventing liver dysfunction in a patient, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day..

3~~14~~. Use of methazolamide in the manufacture of a medicament for reducing elevated liver lipid levels~~content~~ in patient, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.

4~~15~~. Use of methazolamide in the manufacture of a medicament for ~~t~~treating or preventing non-alcoholic fatty liver (NAFL)~~D~~, wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.

5~~16~~. Use of methazolamide in the manufacture of a medicament for treating or preventing non-alcoholic steatohepatitis (NASH), wherein the medicament is for administration of methazolamide at a dosage rate in the range of less than 100 mg to about 80 mg per day.~~The use according to claim 15 for treating or preventing NAFL.~~

6~~17~~. The use according to any one of claims 1-5, wherein the medicament is for administration of methazolamide at a dosage rate of about 90, 85 or 80 mg per day.~~The use according to claim 15 for treating or preventing NASH.~~

7. The use according to claim 6, wherein the medicament is for administration at a dosage rate of about 80 mg per day by administration of a dosage of about 40 mg twice daily.

8~~18~~. The use according to any one of claims 1-7~~12-17~~ wherein the patient is also pre-diabetic or diabetic.

9~~19~~. The use according to any one of claims 1-8~~12-18~~ wherein the patient has an HbA_{1c} level of ≥6.5%.

10~~20~~. The use according to any one of claims 1-9~~12-19~~ wherein the methazolamide is administered in combination with an anti-diabetic agent,

11~~21~~. The use according to claim 10~~20~~ wherein the anti-diabetic agent is metformin or a pharmaceutically acceptable salt thereof.

12. A composition, comprising:
methazolamide,
metformin, and
one or more pharmaceutically acceptable additives,
wherein the weight ratio of methazolamide to metformin in the composition is 1:6.25 – 1:56.25.

13. The composition of claim 12, wherein the methazolamide is present in an amount of 80 mg.

14. The composition of claim 12 or claim 13, wherein the metformin is present in an amount of 500 mg – 4,500 mg.

15. The composition of any one of claims 12-14, wherein the metformin is present in an amount selected from 1,250 mg and 1,545 mg.

16. The composition of any one of claims 12-14, wherein the metformin is present in an amount selected from 500, 750, 850 and 1,000 mg.

17. The composition of any one of claims 12-16 wherein the metformin is a pharmaceutically acceptable salt of metformin.

18. The composition of claim 17, wherein the metformin is metformin hydrochloride.

19. The composition of any one of claims 12-18, wherein the methazolamide and metformin are formulated together as an intimate composition.

20. A combination, comprising:
methazolamide, and
metformin,
wherein the weight ratio of methazolamide to metformin in the combination is 1:6.25 – 1:56.25.

21. The combination of claim 20, wherein the methazolamide is present in an amount of 80 mg.

22. The combination of claim 20 or claim 21, wherein the metformin is present in an amount of 500 mg – 4,500 mg.

23. The combination of any one of claims 20-22, wherein the metformin is present in an amount selected from 1,250 mg and 1,545 mg.

24. The combination of any one of claims 20-22, wherein the metformin is present in an amount selected from 500, 750, 850 and 1,000 mg.

25. The combination of any one of claims 20-24, wherein the metformin is a pharmaceutically acceptable salt of metformin.

26. The combination of claim 25 wherein the metformin is metformin hydrochloride.

27. A composition, comprising:
methazolamide in an amount of 1 mg – 90 mg, and
metformin in an amount of 50 mg – 1,000 mg.

28. The composition of claim 27, wherein the methazolamide and metformin are formulated together as an intimate composition.

29. The composition of claim 27 or claim 28, further comprising one or more pharmaceutically acceptable additives.

30. The composition of any one of claims 27-29, wherein the amount of methazolamide is selected from 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 75 mg, 80 mg and 90 mg.

31. The composition of any one of claims 27-30, wherein the amount of metformin is selected from 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 500 mg, 750 mg, 850 mg and 1,000 mg.

32. Use of methazolamide in the manufacture of a medicament for treating NASH.

33. The use according to claim 32 wherein the methazolamide is for administration at a dosage rate of less than 100 mg to about 80 mg per day.

34. The use according to claim 32 or 33 wherein the methazolamide is for administration at a dosage rate of about 80 mg per day by administration of about 40 mg twice daily.

35. The use according to any one of claims 32-34 wherein the methazolamide is for administration in combination with an anti-diabetic agent.

36. The use according to claim 35 wherein the anti-diabetic agent is metformin or a pharmaceutically acceptable salt thereof.

37. The use according to claim 36 wherein the metformin is metformin hydrochloride.

~~22. A composition for treating or preventing liver dysfunction and/or lowering ALT levels and/or reducing liver lipid levels in a patient said composition comprising methazolamide, together with one or more pharmaceutically acceptable additives.~~

~~23. A combination for use in treating or preventing liver dysfunction and/or lowering ALT levels and/or reducing liver lipid levels in a patient undergoing treatment with an anti-diabetic agent, said combination comprising methazolamide and an anti-diabetic agent.~~